Navigation Links
AMT Presents Positive Results of Phase I/II Study with Lead Product,at Annual Meeting of American Society of Gene Therapy

e). The study was started in August 2005 and finalized in April 2007, and in effect demonstrates the safety and efficacy of AMT-010. All patients are now taking part in a follow-up trial, which will last for 12 months.

Efficacy

The primary endpoints of the study were either median fasting plasma triglyceride (TG) levels after administration of AMT-010 equal to or less than 10 mmol/L, or a 40% reduction in median fasting plasma TG after administration on top of a fat-free diet. For all subjects a substantial reduction of median TG levels was observed. Three patients (one from the low dose and 2 from the mid dose group) hit the primary endpoint, with TG levels below the target level of 10 mmol/L or a 40% reduction in TG levels. In two patients of the mid dose group the reduction of TG coincided with expression of active LPL in the injected muscle at 26-32 weeks after vector administration, which clearly demonstrates long-term expression of the therapeutic gene.

Safety

Furthermore, the study shows that AMT-010 was well-tolerated; there were no drug-related severe adverse events, and no dose-limiting toxicity. There was no measurable sign of local or systemic inflammation and no increase in creatinine phosphokinase concentrations, which implies that the impact on tissue function is limited and not harmful to humans.

About AMT

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT's technology allows long-term gene expression and the specific delivery of therapeutic genes to target organs or tissues. AMT has optimized and validated the production of AAV-based gene therapy vectors. The result is a unique, stable, and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of comp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... (Nasdaq: ENDP ) today announced the successful completion ... West Acquisition Corp., for all of the outstanding shares of ... American Stock Transfer & Trust Company, the depositary for the ... New York City time, on Sept. 17, 2010, the expiration ...
... Products Ltd. announced today that walmart.com is ... is significant because sales velocities are being closely monitored ... retailers dedicate resources to educate and address dysphagia concerns ... crush or grind their meds/supplements and the Power Pill ...
Cached Medicine Technology:Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals 2Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals 3Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals 4VitaCarry(R) Handheld Power Pill Grinder Sales Capturing Retailer's Attention 2
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... R.I. -- Researchers from The Miriam Hospital ... disease (COPD) who are also depressed have difficulty ... to be particularly true for women, and screening ... as part of treatment. The study and its ... Medicine . , Chronic obstructive pulmonary disease ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
(Date:7/9/2014)... 9, 2014) A retrospective study conducted by researchers ... reports that among adults with intellectual and developmental disabilities, ... of years receiving dental care increased. The findings, published ... Dentistry , may help improve interventions designed to address ... , The researchers reviewed the dental records of 107 ...
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... , , VOORHEES, N.J., Sept. ... involving the skin, visceral organs, and airway, causing discomfort and even ... of therapies available for the prevention and treatment of angioedema, and ... acute attacks on this patient population. , , ...
... Calls on Congress to Enact Reform , ... Liability and Access today commended President Obama for acknowledging the need ... Congress to follow the President,s leadership by including reform in pending ... an address to Congress, President Obama said, "I,ve talked to enough ...
... , , , ... announced today that it has established the Edward Neurosciences Institute ... the highest level of stroke care in the world to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090910/CG73991 ) , , ...
... , , GREEN ... to keep a strong, healthy immune system. That means getting enough ... there are body stressors you can,t avoid. Environmental toxins are all ... The effects of these toxins can result in a toxic burden ...
... , , NEW BRUNSWICK, ... New York Giants vs. Washington Redskins game this Sunday, September ... new fight: supporting PSE&G Children,s Specialized Hospital, an inpatient rehabilitation ... life-changing conditions. , , Through an ...
... , ... of Cosmetic Injectables Can be a Felony , ... New York, NY (Vocus) September 10, 2009 -- One year in prison ... cosmetic injectables. As recently as August 2009, five physicians, one nurse and a practice ...
Cached Medicine News:Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2Health News:Broad Health Coalition Applauds President Obama's Commitment to Medical Liability Reform 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 3Health News:The #1 Stay Healthy Secret - Whole Body Cleanse(TM) from Enzymatic Therapy 2Health News:PSE&G Children's Specialized Hospital and New York Giants Team Up to Offer Text to Donate Campaign 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 3
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Micro Blade tip 6900 style, straight. Dimensions: 15.2 mm x 2.5 mm x 6.2 mm....
Needle Knife, straight, full handle, non-reflective, 0.74 mm width....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Medicine Products: